JD

Jakob Dupont

Imugene Limited | Non-Executive Director
Dr Dupont is an industry and drug development expert with more than 20 years of experience specialising in oncology and other therapeutic areas. Dr Dupont is currently the Executive Venture Partner at Sofinnova Investments. Dr Dupont's experience includes NASDAQ listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversaw all research and development, including three clinical stage programs spanning Phase 1 through to Phase 3, and preclinical programs. Other current directorships include Pyxis Oncology (NASDAQ: PYXS); Avenzo Therapeutics and Flagship Pioneering (Scientific Advisory Board). Former directorships in last three years - Apexigen (NASDAQ: APGN) until August 2023. Dr Dupont is member of the Risk Committee.

Company and Role

Company
Title
Tenure
Since
IMU
IMU
Imugene Limited
  • Non-Executive Director
2yrs, 8mthSep 2022

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
IMU
IMU
Imugene Limited
01/07/24339,286N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
IMU
IMU
Imugene Limited
14/02/25
Issued
2,000,000$0.043$86,000Employee Share Ownership Plan
IMU
IMU
Imugene Limited
01/07/24
Exercise
250,000$0.055$13,750Conversion of securities
IMU
IMU
Imugene Limited
01/07/24
Issued
250,000$0.055$13,750Conversion of securities
IMU
IMU
Imugene Limited
12/01/24
Issued
1,000,000$0.120$120,000Issue of securities
IMU
IMU
Imugene Limited
03/10/23
Issued
89,286$0.047$4,196Placement